

Senior Management and Board of Directors

ViroPharma Senior Management



Colin Broom

Vice President, Chief Scientific Officer

Colin Broom, M.D. has served as Vice President, Chief Scientific Officer of ViroPharma since May 2004. From 2000 until 2003 Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. From 1998 to 1999, Dr. Broom served as senior vice president of global clinical development for Hoechst Marion Roussel, now Aventis. From 1984 through 1998, Dr. Broom was with Glaxo and then SmithKline Beecham, where he held positions of increasing seniority in clinical pharmacology in Europe before moving to the US to head global oncology and subsequently becoming Vice President of CNS/GI. Dr. Broom holds a Bachelor of Science degree in pharmacology from University College in London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School. Dr. Broom is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.



Thomas F. Doyle

Vice President, Strategic Initiatives

Thomas F. Doyle is ViroPharma's Vice President, Strategic Initiatives as of January 2008; he previously served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.



Vincent J. Milano

President, Chief Executive Officer and Chairman of the Board of Directors;

Vincent Milano is ViroPharma's President and Chief Executive Officer, and member of the Board of Directors as of March 2008. He joined the company in 1996 and served as vice president, chief financial officer, and treasurer from 1997 to 2006. In 2006, he assumed the role of vice president, chief financial officer and chief operating officer.

Mr. Milano has been instrumental in building ViroPharma, including leading efforts in raising nearly \$900 million in capital and the acquisition of Vancocin(R) from Eli Lilly and Company. He has played a critical role in all business development and investor relations activities of the company, and has contributed significantly to establishing the strategic direction of the company. Prior to joining ViroPharma, he was with KPMG LLP, independent certified public accountants, where he served as senior manager. Mr. Milano received his bachelor of science degree in accounting from Rider College.



Robert G. Pietrusko

Vice President, Global Regulatory Affairs and Quality

Dr. Pietrusko joined ViroPharma in 2007 from his previous post as senior vice president of worldwide regulatory affairs for Millennium Pharmaceuticals, Inc., where was most recently responsible for the global regulatory affairs function and strategy. He was instrumental in the approval of Millennium's products, including the accelerated approval and worldwide regulatory strategy for Velcade, a

product approved in over 75 countries worldwide. Prior to Millennium, he spent 19 years at GlaxoSmithKline, culminating in his tenure as vice president and director, anti-infective and antiviral therapeutic areas, U.S. regulatory affairs, where he led the anti-infective and antiviral regulatory groups. During his tenure at GlaxoSmithKline, he was instrumental in approvals for products including Havrix, Augmentin(R) XR and ES (amoxicillin/clavulanate potassium) for bacterial sinusitis and community-acquired pneumonia, and Infanrix(R) (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed). Dr. Pietrusko has directed the submission of more than 20 NDAs, sNDAs and BLAs to the U.S. Food and Drug Administration (FDA) including antibiotics, anti-virals, vaccines, oncologics, cardiovascular products, pulmonary products and anti

inflammatory compounds. He has been directly responsible for organizing and leading eight FDA Advisory Committee presentations. Dr. Pietrusko holds a Bachelor of Science degree in biology and a Bachelors of Pharmacy degree from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. Dr. Pietrusko is the author of 52 scientific publications.



Daniel B Soland
Vice President, Chief Operating Officer

Daniel B. Soland is ViroPharma's Vice President and Chief Operating Officer as of March 2008. He joined ViroPharma in November 2006 as Vice President and Chief Commercial Officer following his previous post as President of Chiron Vaccines. At Chiron, Soland was most recently responsible for managing the vaccine division to annual sales of \$1 billion. Prior to Chiron, he was the president and chief executive officer of Epigenesis Pharmaceuticals, a privately held biopharmaceutical company engaged in developing drugs for use in asthma, COPD and allergic rhinitis. Prior to that, Mr. Soland spent nine years with GlaxoSmithKline as the vice president and director of worldwide marketing operations, and five years as their vice president and director of the U.S. vaccines business unit. Mr. Soland holds a Bachelor of Science degree in pharmacy from the University of Iowa, in Iowa City, IA.

Charles A Rowland
Vice President, Chief Financial Officer

Charles A. Rowland Jr., CPA, MBA, is ViroPharma's Vice President and Chief Financial Officer. He has 28 years of diversified experience across a broad field of financial areas. Mr. Rowland is responsible for all areas of finance and accounting, including financial reporting, tax, treasury, and strategic financial planning. Most recently, he was the executive vice president and chief financial officer for Endo Pharmaceuticals, as well serving for a period as co-interim chief executive officer. At Endo, Mr. Rowland drove the strategic planning process through two successive chief executive officers. He also led the design and implementation of the company's mid and long-term strategy. Prior to joining Endo, Mr. Rowland spent three years as senior vice president, chief financial officer for Biovail Pharmacueticals, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology. Mr. Rowland previously held positions of increasing

responsibility at Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb Company. He holds a Bachelors of Science in accounting from St. Joseph's University, and a Master of Business Administration degree from the Rutgers University

ViroPharma Board of Directors

Vincent J. Milano; Chairman

Frank Baldino, Jr., Ph.D.; Chief Executive Officer and Chairman of the Board of Directors of Cephalon Inc.

Paul A. Brooke; Managing Director and Co-Founder of venBio; managing member, PMSV Holdings LLC.

William D. Claypool, M.D.; Senior Partner at Penmark Associates, LLC.

Michael Dougherty; President and Chief Executive Officer, Adolor Corporation

Robert J. Glaser; Senior Partner of Penmark Associates

John R. Leone; Partner, Paul Capital Partners

Howard H. Pien; Former President, Chief Executive Officer and Director, Medarex